drugset

drugset / Trial / NCT01621269

ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon

NCT01621269 ↗

Phase 4 Withdrawn Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study to evaluate efficacy of fingolimod in patients with neutralizing antibodies over 12 months

Timeline

Start: 2013-06
Primary completion: 2014-06
Completion: 2014-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fingolimod	Small molecule	—	—

Indications